Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to improve ...

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

For a time, the company looked like a high-upside growth stock. However, that story was put to the test in December, when ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1/1b ...

Arcus senilis is when the cornea of your eye has a white or gray ring or arc around it. Your cornea is the transparent outer covering of your eye. It’s also known as corneal arcus. It’s common in ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21, ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus senilis is a white, gray, or blue arc or ring that develops around the edge of the cornea. It typically appears as an arc that affects the top and bottom of the cornea. According to the American ...

PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig ...